Psilocybin
11
2
2
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 11 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
25%
1 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (11)
Group PACBT for Depression
NeuroGuard: Psilocybin Trial for Preventing Chemo-induced Neuropathy
The Effects of Psilocybin in Healthy Volunteers: Psychological, Biochemical and Electrophysiological Biomarkers.
Pilot Study of Psilocybin-Assisted Therapy for Demoralization in Patients Receiving Hospice Care
Psilocybin-Assisted Physical Therapy in Chronic Low Back Pain
The RECAP2 Study: Midazolam and Psilocybin
Precision Functional Brain Mapping in Psilocybin
PRoMiSS: Psilocybin and the Role of Music in Set and Setting
Evaluation of the Effect of a Single Dose of Psilocybin on Neural Correlates of Cognitive Control in Patients With Psychogenic Nonepileptic Seizures
Psychedelic-assisted Group Program for First Responders
Pilot Study: Effects of Psilocybin on Behavior, Psychology and Brain Function in Long-term Meditators